Your browser is no longer supported. Please, upgrade your browser.
Settings
BCYC Bicycle Therapeutics plc daily Stock Chart
BCYC [NASD]
Bicycle Therapeutics plc
Index- P/E- EPS (ttm)-1.75 Insider Own21.40% Shs Outstand16.76M Perf Week43.81%
Market Cap163.41M Forward P/E- EPS next Y-2.36 Insider Trans- Shs Float4.33M Perf Month41.30%
Income-31.10M PEG- EPS next Q-0.46 Inst Own36.80% Short Float0.60% Perf Quarter-25.57%
Sales10.60M P/S15.42 EPS this Y-34.50% Inst Trans- Short Ratio0.94 Perf Half Y-
Book/sh5.84 P/B1.67 EPS next Y4.80% ROA- Target Price19.50 Perf Year-
Cash/sh6.47 P/C1.51 EPS next 5Y- ROE- 52W Range6.24 - 14.91 Perf YTD-18.75%
Dividend- P/FCF- EPS past 5Y- ROI30.60% 52W High-34.61% Beta-
Dividend %- Quick Ratio12.80 Sales past 5Y- Gross Margin- 52W Low56.25% ATR0.85
Employees61 Current Ratio12.80 Sales Q/Q-11.80% Oper. Margin- RSI (14)68.50 Volatility11.57% 10.53%
OptionableNo Debt/Eq0.00 EPS Q/Q-102.90% Profit Margin- Rel Volume1.45 Prev Close9.13
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume27.92K Price9.75
Recom1.50 SMA2031.61% SMA5022.34% SMA2003.98% Volume40,354 Change6.79%
Sep-11-19Upgrade Goldman Neutral → Buy $14
Jun-17-19Initiated Piper Jaffray Overweight $20
Jun-17-19Initiated Jefferies Buy $22
Jun-17-19Initiated Goldman Neutral $14
Jun-17-19Initiated Canaccord Genuity Buy $22
Aug-08-19 07:00AM  Bicycle Therapeutics Reports Second Quarter 2019 Financial Results and Provides Clinical Update Business Wire
Jul-24-19 08:00AM  Bicycle Therapeutics Enhances Board of Directors Business Wire
Jul-01-19 07:46AM  Bicycle Therapeutics shares soar 29% premarket on news of positive trial of DME treatment MarketWatch
07:30AM  Bicycle Therapeutics Announces Positive Topline Results from Oxurions Phase I Trial Using a Novel Bicycle-based Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema Business Wire
May-23-19 01:09PM  Bicycle Therapeutics shares slide 10.7% in trading debut MarketWatch
09:15AM  Guest Host Tonight and Tomorrow Zacks
08:55AM  Bicycle Therapeutics raises $60.2 million in IPO, Ideaya Biosciences raises $50 million MarketWatch
May-22-19 09:49PM  Bicycle Therapeutics Announces Pricing of Initial Public Offering Business Wire
May-21-19 04:45PM  Bicycle Therapeutics IPO: What You Need To Know Benzinga
Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in preclinical studies targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage, as well as systemically-delivered activators. In addition, it is developing THR-149, a key immune cell co-stimulatory molecule that is in Phase I clinical trials. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, hematology, ophthalmology, and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; and research collaboration agreement with Bioverativ Inc., AstraZeneca AB, and Oxurion NV. The company was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.